Awanish  Kumar

Department Bio Technology
Designation Assistant Professor
Educational Qualification Ph.D Biotechnology (JNU Delhi & CSIR-CDRI); PDF (McGill University, Canada)
E-Mail awanik.bt@nitrr.ac.in; drawanishkr@gmail.com
Contact Number 918871830586
Areas of Interest

Research Area: Antimicrobial Resistance, Drug Targeting, Drug Discovery, & Drug Delivery.

 https://orcid.org/0000-0001-8735-479X

Publications

RECOGNITION

√ Recognized as top 2% scientist of the world  according to Stanford  University and PLOS Biology, USA report- 2020 (10.1371/journal.pbio.3000918)

Profile of Dr. Awanish Kumar in IRINS (Indian Research Information Network System) 

 Ø  Vidwan-ID:112658 (https://nitrr.irins.org/profile/112658)

BIBLIOMETRIC INDICATORS (https://www.scopus.com/authid/detail.uri?authorId=18437170100) 

No. of Paper published in SCI  Journal

Patent Filed

Books

(Full)

 

Book

(Chapters)

Paper in     Int+ Nat Conference

h-index/    Total citations

No. of SCI paper reviewed

Total Impact   Factor

125

02

08

18

(34+29)=63

24/ 1774

(Scopus)

187

(Publons)

352

Detail of published research papers (in year wise descending order): Kumar A* = Awanish Kumar; *Corresponding Author; IF=Impact Factor

 125. Jha A, Vimal A, Kumar A*(2021)Target shortage and less explored multiple targeting: hurdles in the development of novel antifungals but overcome/addressed effectively through structural bioinformatics. Briefings in Bioinformatics (IF: 8.99, Oxford University Press, UK) https://doi.org/10.1093/bib/bbaa343

124. Kumar A*, Kumar A (2021).  Antibiotic resistome of Salmonella Typhi: Molecular determinants for the emergence of drug resistance. Frontiers of Medicine; in press (IF: 3.4, Springer)

 

123. Prusty JS, Kumar A* (2020). Coumarins: Antifungal effectiveness and future therapeutic scope. Molecular Diversity; 24:1367–1383 (IF: 2, Springer)

122. Karn SK, Bhambri A,  Jenkinson IRDuan J,  Kumar A  (2020).  Biomolcules and their possible role in corrosion induction and corrosion inhibition: A possible insight. Corrosion Reviews; 38 (5): 403–421 (IF: 1.9, De Gruyter)

121. Paroha R, Chourasia R, Rai R, Kumar A,  Vyas A Chaurasiya S Singh A (2020).  Host Phospholipase C-γ1 impairs phagocytosis and killing of mycobacteria by J774A.1 murine macrophages. Microbiology & Immunology; 64(10): 694-702 (IF: 1.5, Wiley)

120. Kumar A, Pandey SC, Samant M*  (2020).  A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis. Parasite Immunol; 42(10): e12727 (IF: 2, Wiley)

119. Panigrahy SK, Kumar A*, Bhatt R* (2020).  In Vitro and In Vivo Anti-diabetic Activity of Fractions Obtained from the Unexplored Hedychium coronarium Rhizome. PNAS, India Section B: Biol Sci; 90(3):605–614 (IF: 0.4, Springer)

118. Kumar A* (2020).  Virtual global biorepository: access for all to speed-up result-oriented research. Cell and tissue banking;21(3):361–365 (IF: 1.9, Springer) 

117. Pandey SC, Kumar A*, Samant M* (2020). Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis. Parasite Immunol; 42(9): e12732 (IF: 2, Wiley)

116. Jha A, Kumar A, Kumar A*  (2020).  Subtractive proteome analysis approach divulges promising drug targets in Candida albicans. Int J Peptide Res & Therapeutics; 26(3), 1559-1566 (IF: 1., Springer)

115. Nirala N, Periyasami R, Kumar A* (2020). Study of Skin flow motion pattern using photoplethysmogram. Int J Adv Inteligence Paradigms;16(3/4):241-64 (Scopus)

114. Kumar A, Bharti SK, Kumar A* (2020).  In-vitro characterization of mucoadhesive polysaccharide polymers tablets fabricated using FTIR press. Istanbul J of Pharm; 50(2): 79 – 82. (ESCI) 

113. Kumar A, Pandey SC, Samant M* (2020).  DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment. Acta Tropica; 208: 105512 (IF: 2.5, Elsevier)

112. Behera SS, Sheikha AFE, Hammami R, Kumar A*  (2020). Traditionally fermented pickles: How the microbial diversity associated with their nutritional and health benefits? J of Functional Foods; 70: 103971 (IF: 3.7, Elsevier)

111. Jha A, Kumar A* (2020). Multiple drug targeting potential of novel ligands against virulent proteins of Candida albicans. Int J Peptide Res & Therapeutics; 26 (2): 921–942 (IF: 1.5, Springer)

110. Behera SS, Priyadarshini M, Kumar A* (2020). Optimization for Bio-processing of Elephant foot yam (Amorphophallus paeoniifolius) into Lacto-pickle using Taguchi Statistical approach. J of Food Measur Characterization;14(3): 1470-1480 (IF: 1.6, Springer)

109. Sinha A, Nishant N, Kumar A (2020). A mathematical model of Adiponectin resistance. J Theoretical Biol; 494 (110246) (IF: 2.3, Elsevier)

108. Kumar A, Kumar A* (2020). The virtuous potential of Chitosan oligosaccharide for promising biomedical applications. . J of Materials Research; 35 (9):1123-1134. (IF: 2.5, Cambridge Univ Press)

107. Tripathi S, Parmar J, Kumar A*  (2020). Structure-based immunogenicity prediction of Uricase from fungal (Aspergillus flavus), bacterial (Bacillus subtillis) and mammalian sources using immunoinformatic approach. The Protein J; 39 (2): 133–144 (IF: 1.3, Springer)

106. Bakht A,  Imran M, Khan A, Alam T,  El Hassane A,  Alshammari M, Ajmal N,  Vimal A , Kumar A, Riadi Y  (2020). An Improved Synthesis of Key Intermediate to the Formation of selected Indolin-2-ones Derivatives Incorporating Ultrasound and Deep Eutectic Solvent (DES) Blend of Technique, for some Biological Activities and Molecular Docking Studies. Molecules; 25(5): 1118 (IF: 3.2, MDPI, Switzerland)

105. Jha A, Verma S, Kumar A* (2020). Identification of potential inhibitors targeted for strengthening search of anti-leishmanial therapeutics. Biologia;75:437–445 (IF: 0.8)

104. Kumar A* (2020). Survival strategies of Leishmania parasite inside macrophage and drug resistance: Too many questions and few answers. Current Pharma Reports: 6 (2): 25–27 (ESCI, Springer)

103. Panigrahy SK, Kumar A*, Bhatt R (2020). Hedychium coronarium rhizomes: Promising anti-diabetic and natural inhibitor of α-amylase and α-glucosidase. Journal of Dietary Supplements; 17(1): 81-87. (IF: 2.1, T&F)

102. Jha A, Kumar A* (2019). Biobased technologies for the efficient extraction of biopolymers from waste biomass. Bioprocess and Biosystems Engg; 42(12): 1893-1901. (IF: 3.6, Springer)

101. Jha A, Kumar A* (2019). Anticandidal agent for multiple-targets: the next paradigm in the discovery of proficient therapeutics/overcoming drug resistance. Future Med Chem; 11 (22); 2955–2974. (IF: 3.9, Future Medicine)

100. Kumar A, Kumar A* (2019). Fabrication of eggshell membrane-based novel buccal mucosa mimetic surface and mucoadhesion testing of chitosan oligosaccharide films. J of Materials Research; 34(22): 3777-3786.  (IF: 2.5, Cambridge Univ Press)

99. Kumar A, Sharma P, Shukla KK, Misra S, Nyati KK (2019). Japanese Encephalitis Virus: Associated immune response and recent progress in vaccine development. Microbial Path; 136 (103678):1-10 (IF: 2.9, Elsevier)

98.  Pandey S, Dhami D, Jha A, Shah G,  Kumar A*, Samant M* (2019). Identification of trans-2-cis-8-matricaria-ester from the essential oil of Erigeron multiradiatus and evaluation of its antileishmanial potential by in-vitro and in-silico approaches. ACS Omega; 4 (11): 14640-14649 (IF: 2.8, ACS)

 97. Kumar A* (2019). Transmission of Leishmaniasis from human to other vertebrate: A rapid zooanthroponotic evolution. Int Microbiology; 22 (3): 399–401. (IF: 1.8, Springer)

 96. Jha A, Vimal A, Bakht A, Kumar A* (2019). Inhibitors of CPH1-MAP kinase pathway: ascertaining potential ligands as multi-target drug candidate in Candida albicans. Int J Peptide Res & Therap;25(3):997-1010.(IF:1.5, Springer)

95. Garimella S, Vimal A, Merugu R, Kumar A* (2019). Experimental Optimization of Green Hydrogen Production from Phototrophic Bacteria Rhodobacter sphaeroides. Recent Innov Chemical Engg; 12(2): 98-109 (IF: 1.1, Bentham) 

 94. Behera SS, Panda SH, Panda SK, Kumar A* (2019). Biochemical analysis of Elephant Foot Yam (Amorphophallus paeoniifolius) Lacto-pickle with probiotic L. plantarum. Annals of Microbiology;69(6):577-590.(IF:1.5, Springer)

 93.  Gopal GJ, Kumar A (2019). Why studies on Helicobacter pylori Type IV secretion system is slow? SN     Comprehensive Clinical Medicine; 1(5): 339-341. (Springer)

 92.  Karn SK, Kumar A* (2019). Sludge: Next paradigm for enzyme extraction and energy generation. Preparative Biochem and Biotech; 49 (2): 105–116. (IF: 1.4, T&F)

 91.  Karn SK, Kumar A* (2019). Protease, lipase and amylase extraction and optimization from the activated sludge of pulp and paper industry. Ind J Expt Biol; 57 (3): 201-205. (IF: 1.5, NISCAIR)

 90. Garimella S, Vimal A, Merugu R, Kumar A* (2019). Optimization for Enhanced Hydrogen Production from Rhodobacter sphaeroides using Response Surface Methodology. SN Applied sciences; 1: 156. (Springer)

 89. Pandey SC, Jha A, Kumar A*, Samant M (2019). Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani. Int J of Biological Macromolecules; 121: 480-487 (IF: 5.1, Elsevier) 

 88.  Nirala N, Singh BK, Periyasami R, Kumar A* (2019). Detection of Type-2 Diabetes Using Characteristics of Toe Photoplethysmogram By Applying Support Vector Machine. Biocybernetics and Biomed Engg; 39 (1): 38-51. (IF: 2.5, Elsevier)

87. Jaiswal SKSharma NKKrishnan SKumar APrakash OKumar PKumar ABharti SK (2018). Phytochemicals as uropathognic Escherichia coli FimH antagonist: In vitro and in silico approach. Current Molecular Medicine; 18 (9): 640 – 653. (IF: 2.2, Bentham)

86. Sharma A, Gudala S, Ambati SR, Payra S, Aruna LV, Vedula RR,  Jha A, Kumar A, Penta S, Banerjee S (2018). On Water NiFe2O4 Nanoparticle-Catalyzed One-Pot Synthesis of Biofunctionalized Pyrimidine-Thiazole Derivatives: In-silico Binding Affinity and in-vitro Anti-Cancer Activity Studies.Chemistry Select;3(39):11012-19. (IF: 1.6, Wiley)

 85. Nirala N, Periyasami R, Kumar A* (2018). Non invasive diagnostic methods for better screening of peripheral arterial disease. Annals Vascular Surgery;52(10):263-272(IF: 1.2)

84. Thakur P, Kumar A, Kumar A* (2018). Targeting oxidative stress through antioxidants in diabetes mellitus. J Drug Targeting; 26 (9): 766-776. (IF: 3.3, T&F).

83. Srivastava A, Kumar S, Kumar A* (2018). Targeted therapy of chronic liver diseases with the inhibitors of angiogenesis. Biomedicine & Pharmacotherapy;105; 256-266.(IF: 4.5)

   82. Verma S, Kumar A, Tripathi T, Kumar A* (2018). Muscarinic and Nicotinic acetylcholine receptor agonists:  Current scenario in Alzheimer’s disease therapy. J Pharmacy Pharmacology;70(8):985-993. (IF: 2.5, Wiley)

   81. Shukla R, Shukla H, Kalita P, Sonkar A, Pandey T, Singh DB, Kumar A, Tripathi T (2018). Identification of  potential inhibitors of Fasciola gigantica thioredoxin1: Computational screening, molecular dynamics simulation and binding free energy studies. J Biomol Struct Dyn; 36 (8): 2045-2057. (IF: 3.3, T&F)

   80. Sharma A, Satish S, Ambatia SR, Penta S, Bomma Y, Janapala VR, Jha A, Kumar A (2018). Synthesis, anti-cancer evaluation and molecular docking studies of novel 4-hydroxy-2-thioxo-3,4-dihydro-2H-[1,3]thiazin-6-yl)-chromen-2-ones via multi-component approach. J Chinese Chem Society; 65 (7):810-821. (IF: 1.3, Wiley)

    79. Sinha A, Nishant N, Kumar A* (2018). Rough Set method accurately predicts unknown protein class/family of Leishmania donovani membrane proteome. Mathematical Biosciences; 301: 37-49. (IF: 1.6, Elsevier)

    78. Nirala N, Periyasami R, Kumar A* (2018). Potential of photoplethysmogram for the detection of calcification  and stenosis in lower limb. Int J Bioinfo Res and Applications; 14(3):283-304. (Scopus)

   77.  Vimal A, Kumar A* (2018). L-Asparaginase: A feasible therapeutic molecule for multiple diseases. 3 Biotech; 8 (6)278. (IF: 1.4, Elsevier)

    76. Satish G, Sharma A, Rao VR, Kumar A, Penta S (2018). Recent developments in synthesis of embelin heterocyclic derivatives and their biological applications -A Review. Chemical Papers; 72 (5) 1065–1080. (IF: 1.6, Springer)

    75. Rajendran V, Kalita P, Shukla H, Kumar A,  Tripathi T (2018). Aminoacyl-tRNA synthetases: structure,  function, and drug discovery.  Int J of Biological Macromol; 111:400-414 (IF: 5.1, Elsevier)

   74. Bharti SK, Krishnan S, Kumar A, Kumar A*(2018). Antidiabetic phytoconstituents and their mode of action on metabolic pathways. Therapeutic Adv in Endocrin & Metabol; 9(3) 81–100. (IF: 3.5, Sage)

    73. Kumar A, Pandey SC, Samant M (2018). Slow pace of antileishmanial drug development. Parasitology Open;  4, e4, 1–11. (ESCI, Oxford Press)

    72. Jha A, Kumar A(2018). Deciphering the role of Sodium Lignosulfonate against Candida spp. as persuasive anticandidal agent.  Int J of Biological Macromol;107(A): 1212-1219.   (IF: 5.1, Elsevier) 

    71. Kumar A, Pal D* (2018). Antibiotic resistance and wastewater: correlation, impact and critical human health challenges. J of Environmental Chemical Engg; 6 (1): 52-58. (IF: 4.3, Elsevier)

    70. Vimal A, Jha A, Kumar A* (2018). Eugenol derivatives prospectively inhibit L-asparaginase: a heady target    protein of Salmonella typhimurium. Microbial Pathogenesis; 114: 8-16. (IF: 2.5, Elsevier)

    69. Behera SS, Panda SH, Mohapatra S, Kumar A* (2018). Statistical Optimization of Elephant Foot Yam   (Amorphophallus paeoniifolius) Lacto-pickle for Maximal Yield of Lactic acid. LWT-Food Science and Technology; 87:342-350. (IF: 4.0, Elsevier)

      68. Vimal A, Kumar A* (2017). Spices chemoconstituents as persuasive inhibitor of S. typhimurium virulent protein L-Asparaginase. Letters in Drug Design & Discovery; 14(12):1433-1454 (IF: 1.1, Bentham) 

     67. Pal D, Kumar A, Keshav A, Majumdar B (2017). Production and Recovery of Pyruvic Acid: Recent Advances.  J of Institution of Engineers (India): Series E; 98(2):165-75 (IF: 1.0, Springer) 

     66. Srivastava A, Gupta J, Kumar S, Kumar A* (2017). Gut biofilm forming bacteria in inflammatory bowel disease. Microbial Pathog; 112: 5-14. (IF: 2.5, Elsevier)

     65. Bit A¥, Kumar A¥, Singh AK, Rizvanov AA, Kiassov AP, Patra PK, Kumar M and Bissoyi A (2017). Crosstalk between Substrates and Rho-Associated Kinase inhibitors in Cryopreservation of Tissue Engineered Constructs. Stem Cells Int; Vol. 17,Article ID 1380304, 9 pages. (IF: 3.9, Hindawi)    

      64.  Kumar A, Bharti SK, Kumar A* (2017). Therapeutic molecules against type 2 diabetes: What we have and what are we expecting? Pharmacological Reports; 69 (5): 959–970. (IF: 2.7, Elsevier)    

      63. Thakur P, Kumar A, Patra PK, Kumar A* (2017). A demographic study on relation between uric acid and   diabetes parameters in the Chhattisgarh state of India. Advances in Human Biology; 7(3):124-129. (ESSI, WC)

       62. Kumar S, Gupta J, Mohan A, Kumar A* (2017). Structure Prediction and Drug Designing of a Target Protein CPEB4 on In-Silico Platform for Angiogenesis and Chronic Liver Disease. J of Pharmacovig  Pharmacotherapeutics; 02:1-6 (Scopus)

       61. Panigrahy SK, Kumar A*, Bhatt R (2017). Antioxidant potentials of successive solvent extracts from the unexplored Hedhychium coronarium rhizome. J of Food Science and Technology; 54(10):3297–3306. (IF: 1.9, Springer).

       60. Karn  SK,  Eswari SJ, Rajput VD, Rana S,  Kumar A* (2017). Modeling of Simultaneous Application of Vibrio sp. (SK1) and Biochar Amendment for Removal of Pentachlorophenol in Soil. Environmental Engineering Science; 34(8):551-561. (IF: 1.6, MAnnL) 

 59. Vimal A, Kumar A* (2017). Biotechnological production and practical application of L-asparaginase enzyme. Biotechnology Genetic Engg Rev; 33(1):40-61.(IF: 1.9, T&F)

 58. Vimal A, Pal D, Tripathi T, Kumar A* (2017). Eucalyptol, Sabinene and Cinnamaldeyde: Potent inhibitors of  Salmonella Target Protein L-asparaginase. 3 Biotech; 7(4):258.(IF: 1.8,Elsevier)

57. Athanerey A, Patra PK, Kumar A* (2017). Mesenchymal stem cell in venous leg ulcer: An intoxicating therapy. Journal of Tissue Viability; 26(3):216-223 (IF: 2.4, Elsevier)

56. Pal D,  Keshav A, Thakre N, Kumar A, Singh D (2017). Liquid-liquid extraction equilibrium for pyruvic acid recovery: experimental data and modeling. Brazilian J of Chem Engg (IF: 1.0, Brazilian Chem Soc)

55. Singh AK, Jha A, Bit A, Kiyasov A, Rizvanov AA, Ojha A, Bhoi P, Patra PK, Kumar A*, Bissoyi A* (2017). Selaginella bryopteris aqueous extractimproves stability and function of cryopreserved human mesenchymal stem cell. Oxidative Medicine and Cellular Longevity; Article ID 8530656, 10 pages (IF: 5.0, Hindawi) 

54. Vimal A, Kumar A* (2017). Morpheein Model of Allosterism: A remedial step for targeting virulent L-asparaginase. Drug Discovery Today; 22 (5): 814-822 (IF: 7.3, Elsevier)

53. Behera S, Das U, Kumar A, Bissoyi A, Singh AK (2017). Chitosan/TiO2 composite membrane improves proliferation and survival of L929 fibroblast cells; application in wound dressing and skin regeneration. Int J of Biological Macromolecules; 98: 323-343 (IF: 5.1, Elsevier).

52. Kumar A, Kumar A* (2017). Development and characterization of tripolymeric and bipolymeric composite films using glyoxal as a potent crosslinker for biomedical application. Materials Science and Engineering: C; 73: 333–339. (IF: 5.8, Elsevier)

 51. Vimal A, Kumar A*(2017). In vitro screening and in silico validation revealed key microbes for higher production of significant therapeutic enzyme L-asparaginase. Enzyme and Microbial Technol; 98:9-17 (IF: 3.4, Elsevier).

50. Kumar S, Shukla R, Ranjan P, Kumar A* (2017). Interleukin-10: A compelling therapeutic target in the patients with irritable bowel syndrome. Clinical Theraputics; 39 (3) 632-643 (IF: 3.1, Elsevier)

49. Panigrahy SK, Bhatt R, Kumar A* (2017). Reactive oxygen species: Sources, consequences and targeted therapy in Type-II Diabetes. J Drug Targeting;25(2);93-101(IF:3.3)

47. Sinha AK,  Singh P,  Prakash A, Pal D, Dube A, Kumar A* (2017). Putative drug and vaccine target identification in Leishmania donovani membrane proteins using Naïve Bayes probabilistic classifier. IEEE/ACM Transactions on Comp Biology and Bioinformatics; 14 (1) 204-211 (IF: 3.0, IEEE).

         46. Kumar A* and Pal D (2016). Targeting alzheimer’s disease through molecular docking approach. Academic Journal of Science, 06(01):123–130. (Scopus)

45. Kumar A, Nayak BP, Kumar A* (2016). Obesity: single house for many evils. Minerva Endocrinol; 41(4):499-508.  (IF: 1.4, Minerva Medica).

         44. Pandey AK, Sarada DVL, Kumar A* (2016). Microbial decolorization and degradation of Reactive Red 198 azo dye by a newly isolated Alkaligenes species. PNAS, India Sec B: Biol Sci; 86(4):805–815. (IF: 0.4, Springer).

43. Jha A, Kumar A* (2016).  Development and targeting of transcriptional regulatory network controlling FLU1 activation in C. albicans for novel antifungals. J of Mol Graphics & Modelling; 69:1-7. (IF: 2.0, Elsevier)

42. Vimal A, Eswari JS, Kumar A* (2016). Bioprocess modeling for the prediction of therapeutic enzyme l-asparaginase activity in solid state fermentation using multiple linear regression and ANN. Int J of Pharmacy & Pharmaceutical Sci; 8(7)420-426. (IF: 0.6, Innova)

41. Bissoyi A¥, Kumar A¥, Rizvanov A, Nesmelov A, Gusev O, Patra PK, Bit A (2016). Recent Advances And Future Direction In Lyophilisation And Desiccation Of Mesenchymal Stem Cells. Stem Cells International; Vol 2016, Article ID 3604203, 9 pages (IF: 3.8, Hindawi)

40. Thakre N, Prajapati, A, Mahapatra, S, Kumar A; Khapre  A,  Pal D (2016). Modeling and Optimization of Reactive Extraction of Citric Acid. J of Chemical & Engineering Data; 61 (7), 2614–2623. (IF: 2.3, ACS)

39. Kumar A, Vimal A, Kumar A* (2016). Why Chitosan? From properties to perspective of mucosal drug delivery. Int J of Biol Macromol; 91; 615-622. (IF: 5.1, Elsev)

38. Vimal A, Kumar A* (2016). L-Asparaginase as Morpheein: A Potential Drug Target. Pharmacological Research; 111:101. (IF: 5.8, Elsevier)

37. Kumar A, Samant M (2016). DNA vaccine against visceral leishmaniasis: a promising approach for prevention & control. Parasite Immunol; 38(5):273-81. (IF: 2.0, Wiley)

36. Nisha CM, Kumar A, Nair P, Gupta N, Silakari C, Tripathi T, Kumar A* (2016). Molecular Docking and In-Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-Secretase. Advances in Bioinformatics; Vol 2016, Article ID 9258578, 6 pg (ESCI, Hindawi)

35. Nisha CM, Kumar A, Vimal A, Bai BM, Pal D, Kumar A* (2016). Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor. J of Mol Graphics & Modelling; 65; 100–107. (IF:2.0, Elsevier)

34. Bharti SK,   Krishnan S, Kumar  A* (2016). Phytotherapy for diabetes mellitus: Back to nature. Minerva Endocrinol; 41(1):143-146. (IF: 1.4, Minerva Medica)

33. Pal D, Thakre N, Kumar A, & Keshav A (2016). Reactive Extraction of Pyruvic acid Using Mixed Extractants. Separation Science &  Tech; 51(7): 1141-1150. (IF: 1.7, T & F)

32. Kumar A, Nisha CM, Silakari C, Sharma I, Gupta N, Nair P, Kumar A* (2016). Current and Novel Therapeutic Molecules and Targets in Alzheimer’s Disease. J Formos Med Assoc; 115;3-10. (IF: 3.0, Elsevier)

31. Chaturvedi AD, Pal D, Penta S, Kumar A* (2015). Ecotoxic heavy metals transformation by bacteria and fungi in aquatic ecosystem. World J Microbiol Biotechnol; 31(10):1595-1603. (IF: 2.4, Springer)

30. Karn SK and Kumar A* (2015). Hydrolytic enzyme protease in sludge: Recovery and its application. Biotechnology  Bioprocess Eng; 17(5):923-931. (IF: 1.4, Springer)

29. Bharti SK, Krishnan S, NK Sharma, Kumar A, Prakash O, Gupta AK, Kumar A* (2015). In vivo and in silico Investigation of Antidiabetic Activity of Fruit of Withania coagulans Dunal. Current Hypertension Rev; 11(2):143-158. (ESCI, Bentham)

28. Kumar A, Samant M, Misra P,  Khare P, Sundar S, Garg R, Dube A* (2015). Immunostimulatory potential and proteome profiling of Leishmania donovani soluble exogenous antigens. Parasite Immunol; 37(7):368-375. (IF: 2.0, Wiley)

27. Chhetri G, Pandey T, Chinta R, Kumar A*, Tripathi T (2015). An improved method for high-level soluble expression and purification of recombinant amyloid-beta peptide for in vitro studies. Protein Express & Purification; 114:71-76. (IF: 1.5, Elsevier)

26. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A* (2015). Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. Parasitology International; 64(4) 36-42. (IF: 2.1, Elsevier)

25. Bharti SK,  Kumar A, Krishnan S, Gupta AK, Kumar  A* (2015). Mechanism-based antidiabetic activity of Fructo- and isomalto-oligosaccharides: Validation by in vivo, in silico and in vitro interaction potential. Process Biochem; 50, 317-327. (IF: 2.9, Elsevier)

24. Gopal GJ, Pal J, Kumar A, Mukhopadhyay G* (2015). C-terminal domain of CagX is responsible for its interaction with CagT protein of Helicobacter pylori type IV secretion system. Biochem Biophys Res Commun; 464(1):98-103. (IF: 2.9, Elsevier)

23. Mishra PK, Sinha A, Teja KR, Bhojwani N, Sahu S, Kumar A* (2014). A Computational Modeling for the Detection of Diabetic Retinopathy Severity. Bioinformation; 30;10(9):556-561. (Scopus)

22. Kumar A, Bharti SK, Kumar A* (2014). Type 2 Diabetes Mellitus: The Concerned Complications and Target Organs. Apollo Medicine; 1 (9): 161-166. (ESCI, Elsevier)

21. Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S, Dube A* (2014). Studies on characterization of Proliferating Cell Nuclear Antigen of Leishmania donovani clinical isolate and its association with antimony resistance. Antimicrob Agents Chemother; 58(6):2997-3007. (IF: 4.9, ASM)

20. Gopal GJ, Kumar A, Pal J, Mukhopadhyay G* (2014). Molecular characterization and polyclonal antibody generation against core component CagX protein of Helicobacter pylori type IV secretion system. Bioengineered; 5(2), 107–113. (IF: 2.2, Taylor & Francis)

19. Pandey AK, Kumar A* (2014). Improved production strategies and multifarious applications of a natural biopolymer Epsilon-Poly-L-Lysine. Process Biochem; 49, 496–505. (IF: 2.9, Elsevier)

18. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A* (2014). Mass spectrometry based proteomic analysis of L. donovani soluble proteins in Indian clinical isolate. Pathog Dis 70(1):84-87. (IF: 2.4, Oxford)

17. Kumar A, Dhamgaye S, Maurya IK, Singh A, Sharma M, Prasad R* (2014). Curcumin targets cell wall integrity via calcineurin mediated signaling in Candida albicans.  Antimicrob Agents Chemother; 58(1):167-175. (IF: 4.9, ASM)

16. Bharti SK, Kumar A, Sharma NK, Prakash O, Jaiswal SK, Krishnan S, Gupta AK, Kumar A* (2013). Tocopherol from seeds of Cucurbita pepo against diabetes: Validation by in vivo experiments supported by computational docking. J Formos Med Assoc; 112 (11), 676-690. (IF: 3.0, Elsevier)

15. Gopal GJ, Kumar A* (2013). Strategies for the production of recombinant protein in Escherichia coli. Protein J; 32(6):419-425. (IF: 1.3, Springer)

14.Yadav J, Kumar A, Mahorm P, Goel AK, Yadava PK, Kumar P* (2013). Distribution of airborne microbes and antibiotic susceptibility pattern of bacteria during Gwalior fair. J Formos Med Assoc.13;1-8.(IF: 3.0, Elsevier)

13. Kumar A, Misra P, Dube A* (2013). AFLP: an adept technique for genome mapping, genetic differentiation and intraspecific variation in protozoan parasites. Para Res; 112 (2):457-466. (IF: 2.0, Springer)

12. Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A* (2010). Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in Sodium Antimony Gluconate resistant clinical isolate of Leishmania donovani. British J of Clinical Pharmacology; 70(4):609-617. (IF: 3.7, Wiley)

11. Misra P, Sashidhara KV, Singh SP, Kumar A, Chaudhaery SS, Gupta SS, Majumder HK, Saxena AK, Dube A* (2010). 16α-hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. British J. of Pharmacology; 159, 1143-1150. (IF: 7.7, Wiley)

10. Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A* (2010). Amplified Fragment Length Polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. Acta Tropica; 113(2):202-206. (IF: 2.5, Elsevier)

Ø E

Other Info.

EXPERIENCE HIGHLIGHTS/ACHIEVEMENT SUMMARY

Research Experience        (Post-Ph.D)

Teaching Experience         (Post-Ph.D)

GATE &  NET (CSIR-UGC) qualified

International Reviewer Merit-Point 

Reviewer for  SCI journals

RG Score

Ph.D. Thesis Guided

Awards received

12 years

08 years

GATE AIR-31     NET with JRF

200

102

45.7

06

14

POSITIONS HELD 

  • 2013–Present  :  Asstt. Professor, National Institute of Technology (NIT), Raipur, India     
  • 2011–2013      :  Postdoctoral Fellow, Jawaharlal Nehru University (JNU), New Delhi, India
  • 2009-2010       :  Postdoctoral Fellow, McGill University (MGU), Montreal, Canada
  • 2008-2009       :  Lecturer, National Institute of Pharma Edu & Research (NIPER), Hajipur, India 

 RESEARCH SUPERVISION

  • Ph.D.    : 06 (Completed), 02 (On-going). 
  • PG        : 06 (Completed). 
  • UG        : 39 (Completed), 4 (On-going).

SPONSORED RESEARCH PROJECTS 

SN

Funding Agency

Role

Status

3

DBT (Indo-USA grant)

PI

Ongoing

2

CCOST (Mini research grant)

PI

Completed

1

UGC (Early career grant)

PI

Completed

RESEARCH GRANT PROPOSALS REVIEWED: 1. National Science Center (NSC), Poland; 2. Departments of Science & Technology (DST), India.

RESEARCH PAPERS REVIEWED: 164 from various SCI journals of ACS, Bentham, Dove, Elsevier, Hindawi, MA Liebert, Medknow, Nature, PLoS, Springer, T&F, Wiley.

EXTERNAL EXAMINER/REVIEWER FOR Ph.D. THESIS: 03

CONFERENCES/WORKSHOPS ORGANIZED06

CURRICULUM/SYLLABUS DESIGNED: For many institute/universities.

COURSES TAUGHT

  • UG level: 1. Animal Biotechnology, 2. Analytical Techniques, 3. Biosafety and Bioethics, 4. Cell & Molecular Biology, 5. Genomics, 6. Plant Biotechnology, 7. RDT.
  • PG level: 1. Biochemistry, 2. Cell Biology, 3. Microbiology, 4. Molecular Biology, 5. Proteomics. 
  • Ph.D. level: 1. Biochemistry, 2. Bio-instrumentation, 3. Enzyme Technology

AWARDS/SCHOLARSHIPS

  1. Global Peer Review Awards, Publons (Clarivate Analytics), Philadelphia ,USA : 2019
  2. Young Scientist/research investigator award from UGC, New Delhi, India: 2011
  3. Excellent research award from CSIR- CDRI, Lucknow, India: 2011
  4. Postdoctoral Fellowship from Canadian Institute of Health Research (CIHR), Canada : 2009
  5. Senior Research Fellowship from CSIR-UGC (Govt. of India), New Delhi (India) for Ph.D. : 2007
  6. Junior Research Fellowship from CSIR-UGC (Govt. of India), New Delhi, (India) for Ph.D. : 2005
  7. Awarded National Eligibility (NET) for Lectureship with JRF from CSIR-UGC, New Delhi, India : 2004 & 2005
  8. Awarded Junior Research Fellowship (JRF) from Dept. of Biotechnology, New Delhi, India: 2004
  9. National Merit Scholarship for PG from Department of Biotechnology, Govt. of India, New Delhi, India : 2002

INTERNATIONAL AND NATIONAL HONOURS

  • 2018-Present : Member, Indo-US Science and Technology Forum (IYSTF)
  • 2015-Present: Member, Massive Open Online Courses (MOOCs) of MHRD, NIT Raipur
  • 2014-2016: Member Secretary, Institutional Ethical Committee (IEC), NIT, Raipur.
  • 2013-Present: Member, Global Foodborne Infections Network, Centre for Disease Control (CDC), USA.
  • 2013-Present: Advisor, Bioinfo-Drug Target, USA.

ADVISORY BOARD/COMMITTEE

  • 2018-Present: Member, International Research Collaboration Cell, NIT Raipur
  • 2014-Present: Member, Departmental Academic, Purchase, Doctoral Research committee of NIT, Raipur.
  • 2013-Present: Member; Institutional Anti Ragging committee, NIT, Raipur.
  • 2013-2015    : Member, Task force, Industry Institute Interaction (III) Cell, NIT Raipur
  • 2008-2009   : Member; Examination Board Moderation Committee, Library Committee, Institutional Purchase Committee, Scientific Review Committee of NIPER, Hajipur.